Actinium Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted radiotherapies. The company's proprietary platform combines monoclonal antibodies with potent radioisotopes, specifically alpha-emitters like Actinium-225 (Ac-225) and beta-emitters like Iodine-131, to selectively target and destroy cancer cells while sparing healthy tissue. Its lead clinical programs include Iomab-B, a targeted conditioning agent designed to prepare patients for bone marrow transplants, and Actimab-A, a CD33-targeted therapy for acute myeloid leukemia (AML). Actinium is also advancing ATNM-400, a novel Ac-225 antibody radioconjugate targeting solid tumors such as prostate, lung, and breast cancers.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical pipeline into solid tumors using ATNM-400, a first-in-class Actinium-225 antibody radioconjugate targeting a novel, non-PSMA antigen.
Expected impact: Positions the company to address massive solid tumor markets, including prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer, bypassing limitations of PSMA-targeted therapies.
Developing Actimab-A as a mutation-agnostic backbone therapy for myeloid malignancies, including relapsed/refractory acute myeloid leukemia (AML).
Expected impact: Aims to establish a new standard of care in AML by achieving high rates of MRD-negative complete remissions and improving overall survival.
Building out manufacturing infrastructure, including proprietary Actinium-225 cyclotron manufacturing technology, to secure isotope supply.
Expected impact: Provides end-to-end control over the radioisotope supply chain, mitigating industry-wide shortages of Actinium-225 and facilitating strategic partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures a reliable and constant supply of high-quality Actinium-225 (Ac-225) to advance clinical development of Actimab-A and other early and late-stage candidates globally.
Terms: Financial terms were not publicly disclosed.
Collaborating on the clinical development of Actimab-A in AML and other myeloid malignancies, including evaluating triplet combinations in frontline AML.
Terms: Collaborative research framework with shared development responsibilities.